Akdis Mübeccel
Swiss Institute of Allergy and Asthma Research (SIAF), Obere Strasse 22, CH-7270 Davos, Switzerland.
Curr Opin Immunol. 2006 Dec;18(6):738-44. doi: 10.1016/j.coi.2006.06.003. Epub 2006 Oct 4.
The specific immune response to allergens is decisive in the development of clinically healthy or allergic states. In healthy individuals, the B-cell response varies between there being no response and the production of IgG(4)- or IgG(1)-dominating allergen-specific antibodies in the presence or absence of low amounts of IgE. If a detectable immune response is mounted, T regulatory type 1 (Tr1) cells specific for common environmental allergens consistently represent the dominant subset in healthy individuals. Exposure to high doses of allergens leads to a high concentration of specific IgG(4), detectable IgE and a Tr1 type of immune response. Induction of IL-10- and TGF-beta-producing Tr1 cells, IgG(4) isotype blocking antibodies, and suppressed mast cells, basophils and eosinophils represent major components of a relatively normalized immune response after allergen-specific immunotherapy (SIT).
对过敏原的特异性免疫反应在临床健康或过敏状态的发展中起决定性作用。在健康个体中，B细胞反应有所不同，在没有反应与在存在或不存在少量IgE的情况下产生以IgG(4)或IgG(1)为主的过敏原特异性抗体之间变化。如果引发了可检测到的免疫反应，针对常见环境过敏原的1型调节性T（Tr1）细胞在健康个体中始终是主要亚群。暴露于高剂量过敏原会导致特异性IgG(4)、可检测到的IgE浓度升高以及Tr1型免疫反应。诱导产生IL-10和TGF-β的Tr1细胞、IgG(4)同种型阻断抗体以及抑制肥大细胞、嗜碱性粒细胞和嗜酸性粒细胞是过敏原特异性免疫疗法（SIT）后相对正常化免疫反应的主要组成部分。
